FDA AP — CHILDREN'S ALLEGRA HIVES (SUPPL)

FDAhigh relevance

Sub-indication match (ild); Entity match (chattem sanofi)

FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

FDAhigh relevance

Sub-indication match (ild); Regulatory pathway relevance (approval)

FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)

FDAhigh relevance

Sub-indication match (ild)

FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)

FDAhigh relevance

Sub-indication match (ild)

FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)

FDAhigh relevance

Sub-indication match (ild)

Lower dose needle-free allergy treatment approved for younger children

MHRAhigh relevance

Sub-indication match (ild)

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients

FDAlow relevance

Weak alignment to signal sub-indication and entities

FDA Approves First Nonprescription Fixed-Dose Combination of Acetaminophen and Naproxen Sodium for 12-Hour Pain Relief

FDAlow relevance

Weak alignment to signal sub-indication and entities

Safe, Effective and Cost-Effective Oxygen Saturation Targets for Children and Adolescents With Respiratory Distress: Randomized Controlled Trial

ClinicalTrials.govhigh relevance

Sub-indication match (ild)

Risk Factors for Drug-Resistant Epilepsy in Children

ClinicalTrials.govhigh relevance

Sub-indication match (ild)

Nutritional Care After Discharge in Children Term Born-18years Old

ClinicalTrials.govhigh relevance

Sub-indication match (ild)

Two-Year Follow-up Study on Children Exposed to Trauma

ClinicalTrials.govhigh relevance

Sub-indication match (ild)

Reducing Disparities in Behavioral Health Treatment for Children in Primary Care

ClinicalTrials.govhigh relevance

Sub-indication match (ild)

A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

ClinicalTrials.govhigh relevance

Sub-indication match (ild)

Interacting With Children Training for Undergraduates

ClinicalTrials.govhigh relevance

Sub-indication match (ild)

Hydrus® Microstent New Enrollment Post-Approval Study

ClinicalTrials.govlow relevance

Weak alignment to signal sub-indication and entities

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

Merckhigh relevance

Sub-indication match (ild); Sponsor/company relevance (Merck)

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Pfizermedium relevance

Sponsor/company relevance (Pfizer)

FDA Approves Supplemental Application for QTERN (Dapagliflozin/Saxagliptin)

Humanexa Signalsmedium relevance

Sponsor/company relevance (AstraZeneca)

FDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride)

Humanexa Signalslow relevance

Weak alignment to signal sub-indication and entities

Decoding osteosarcoma pathogenesis: the pivotal influence of m(6)A modification.

PubMedhigh relevance

Sub-indication match (ild)

Mapping family involvement in music therapy for children and adolescents with cancer: a scoping review.

PubMedhigh relevance

Sub-indication match (ild)

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).

PubMedhigh relevance

Sub-indication match (ild)

Analysis of risk factors for postoperative wound healing in children with bone cysts.

PubMedhigh relevance

Sub-indication match (ild)

Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.

PubMedlow relevance

Weak alignment to signal sub-indication and entities

The dual role of exosomes in renal fibrosis and their potential for clinical translational applications.

PubMedlow relevance

Weak alignment to signal sub-indication and entities